AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22676330
Drug: FREMS and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FREMS and topical treatment (Group A)
Trial: 22676330
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment alone (Group B)
Trial: 18778138
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy treatment for alcohol dependence
Trial: 15641125
Drug: Methylphenidate (5
RxNorm normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (5 mg/day increasing to 20 mg/day)
Trial: 15641125
Drug: Sertraline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (25 mg/day increasing to 100 mg/day)
Trial: 9915366
Drug: Intrathecal baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal baclofen (ITB) 50 microg bolus injection followed by continuous infusion of 302 microg per day
Trial: 7035598
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of stilboestrol and ethisterone therapy during pregnancy
Trial: 7035598
Drug: Inactive tablet
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive tablet (control)
Trial: 23578678
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose CTP (80 mAs)
Trial: 23578678
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose CTP (100 mAs)
Trial: 11337737
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AWL with low-pressure pneumoperitoneum (3 to 4 mm Hg)
Trial: 9429053
Drug: self‐administered subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐administered subcutaneous recombinant human erythropoietin (rhEPO) at a dose of 60 U.kg‐1 BW three times a week and oral iron treatment (ferrofumarate)
Trial: 9429053
Drug: self‐administered subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐administered subcutaneous recombinant human erythropoietin (rhEPO) and oral iron treatment
Trial: 9429053
Drug: self‐administered subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐administered subcutaneous recombinant human erythropoietin (rhEPO)
Trial: 7939760
Drug: 135 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg/m2 given as a single dose over 1 hour
Trial: 7939760
Drug: 135 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg/m2 given in divided hourly daily doses for 3 days
Trial: 26214630
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy with 4 cycles of carboplatin and etoposide followed by conformal 3-dimensional (3D) radiotherapy (RT)
Trial: 26214630
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with cisplatin and etoposide and conformal RT, followed by two cycles of consolidation chemotherapy with carboplatin and etoposide
Trial: 19011437
Drug: Bilastine 80
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Bilastine 80 mg
Trial: 12430112
Drug: Fentanyl 10
RxNorm normalized name: FENTANYL 100MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 10 micro g added to 0.5% hyperbaric ropivacaine 18 mg
Trial: 12430112
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.2 mL added to 0.5% hyperbaric ropivacaine 18 mg
Trial: 8942891
Drug: Adjunctive subconjunctival
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive subconjunctival mitomycin C (MMC)
Trial: 8942891
Drug: No adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjunctive mitomycin C (Control)
Trial: 31780589
Drug: Clinically-supervised gradual
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically-supervised gradual reduction of antipsychotic medication leading to discontinuation when possible
Trial: 31780589
Drug: Clinically-supervised gradual
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically-supervised gradual reduction of antipsychotic medication
Trial: 27684802
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) at 4.33 μg/kg combined with sufentanil (SUF) at 3.0 μg/kg via PCIA
Trial: 22497754
Drug: Lamotrigine extended-release
RxNorm normalized name: Lamotrigine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine extended-release (LTG XR)
Trial: 12582834
Drug: Prazosin (alpha(1)-adrenergic
RxNorm normalized name: prazosin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (alpha(1)-adrenergic antagonist), single oral dose
Trial: 11187913
Drug: Therapy based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy based on the Berlin‐Frankfurt‐Münster 76/79 study
Trial: 1625101
Drug: rHuEPO, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO, 400 IU/kg three times a week plus iron, 20 mg/wk intravenously
Trial: 6387184
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg trimethoprim (20 patients)
Trial: 28980368
Drug: Target dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target dose enalapril (20 mg/day)
Trial: 28980368
Drug: Below-target dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Below-target dose enalapril (5-10 mg/day)
Trial: 28980368
Drug: Target dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target dose placebo (20 mg/day)
Trial: 28980368
Drug: Below-target dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Below-target dose placebo (5-10 mg/day)
Trial: 28980368
Drug: Target dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target dose enalapril vs. below-target dose enalapril
Trial: 11959616
Drug: Water treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water treatment with praziquantel
Trial: 7503194
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline (n = 50)
Trial: 7503194
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline (n = 41)
Trial: 7503194
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no oral terbutaline, n = 53)
Trial: 7503194
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no oral terbutaline, n = 40)
Trial: 2188763
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg APD intravenously
Trial: 25563826
Drug: Furosemide (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (0.2 mg/kg/h, up to 0.8 mg/kg/h)
Trial: 25563826
Drug: Ethacrynic Acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic Acid (0.2 mg/kg/h, up to 0.8 mg/kg/h)
Trial: 23975856
Drug: Radiofrequency (RF)
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency (RF) shrinkage treatment
Trial: 21120480
Drug: Cediranib administered
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib administered in fed state
Trial: 21120480
Drug: Cediranib 30
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 30 mg/day (fixed-dose)
Trial: 21120480
Drug: Cediranib administered
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib administered in fasted state
Trial: 19434533
Drug: Postoperative intraperitoneal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy
Trial: 19434533
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy regimen with Oxaliplatin
Trial: 19434533
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy regimen with Cisplatin
Trial: 10692004
Drug: Encapsulated fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated fish oil (FO) providing 2.1 g eicosapentaenoic acid (EPA) plus 1.1 g docosahexaenoic acid (DHA) per day for 12 weeks
Trial: 3896665
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dimetophrine
Trial: 26899862
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone (8 mg mixed with ropivacaine)
Trial: 25514302
Drug: Lamivudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (100 mg daily)
Trial: 17638396
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (16.6mg nicotine/patch) in former smokers (group 2)
Trial: 16054963
Drug: Contraceptive patch
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive patch (n = 846)
Trial: 16054963
Drug: Oral contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraception (OC) (n = 643)
Trial: 12134249
Drug: Intranasal interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal interferon (IFN)‐alpha2b (6 x 10(6) U every 12 h x 3) plus oral chlorpheniramine (12 mg extended release) and ibuprofen (400 mg) every 12 h for 4.5 days (n=59 subjects)
Trial: 12134249
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo plus oral chlorpheniramine and ibuprofen (n=61 subjects)
Trial: 12134249
Drug: Intranasal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal and oral placebos (n=30 subjects)
Trial: 11756911
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of music and patient-controlled sedation with a mixture of propofol and alfentanil
Trial: 11756911
Drug: Music alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music alone with diazemuls and meperidine administered intravenously if requested
Trial: 11756911
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of music and patient-controlled sedation
Trial: 2904237
Drug: Daily treatment
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment with streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months (2SHRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Trial: 2904237
Drug: Daily treatment
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment with isoniazid, rifampin, and pyrazinamide for 1 month (1SHRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Trial: 2904237
Drug: Daily treatment
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment with isoniazid, rifampin, and pyrazinamide for 2 months without streptomycin (2HRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Trial: 2904237
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with drug‐susceptible strains pretreatment
Trial: 2904237
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with strains resistant to isoniazid, streptomycin, or both drugs pretreatment
Trial: 29189607
Drug: K12 (2.5 × 10(9)
RxNorm normalized name: povidone K12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K12 (2.5 × 10(9) cfu per lozenge)
Trial: 26852498
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intermittent pneumatic compression, kinesio-taping, and underwater massage shower
Trial: 18055869
Drug: Fludarabine (single-agent)
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (single-agent)
Trial: 18055869
Drug: Fludarabine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine monotherapy
Trial: 18055869
Drug: DAT status
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAT status at initiation of therapy
Trial: 16476713
Drug: Celecoxib (CBX)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib (CBX) 200 mg/24 h
Trial: 16476713
Drug: Aceclofenac (ACF)
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac (ACF) 100 mg/12 h
Trial: 11099750
Drug: INN 00835
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INN 00835 (0.2 mg/kg subcutaneously for 5 consecutive days)
Trial: 9368550
Drug: t-PA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t-PA treatment
Trial: 1311535
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of mivacurium at a rate of 6 +/- 2 micrograms.kg‐1.min‐1 after an initial bolus of 2 x ED95.
Trial: 1311535
Drug: Repeated injection
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated injection of mivacurium at 0.6 x ED95 whenever twitch tension recovered to 25% of control.
Trial: 1311535
Drug: Neostigmine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (7 micrograms/kg) administered at 25% twitch recovery in both groups.
Trial: 28285208
Drug: Varenicline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline and cognitive-behavioral therapy for smoking cessation
Trial: 19387697
Drug: Wallis interspinous
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wallis interspinous implant (group W)
Trial: 16452735
Drug: Enoxaparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (30 mg, administered subcutaneously twice a day) starting 24-48 hours after blunt trauma
Trial: 14747633
Drug: Fluoxetine, Paroxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine, Paroxetine, or Sertraline (SSRI antidepressants)
Trial: 2441458
Drug: Elmiron 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elmiron 200 mg X 2 daily
Trial: 22357109
Drug: Intracoronary abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary abciximab (0.25 mg/kg bodyweight bolus followed by 12 h intravenous infusion at 0.125 μg/kg per min)
Trial: 21115882
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg orally twice daily for 9 months
Trial: 15893193
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 2 g/day
Trial: 8661572
Drug: IV butylscopolamine
RxNorm normalized name: butylscopolamine
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV butylscopolamine (20 mg)
Trial: 8661572
Drug: Oral dicyclomine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dicyclomine (20 mg)
Trial: 30745582
Drug: NK105 (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK105 (65 mg/m2)
Trial: 30745582
Drug: Paclitaxel (PTX)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (PTX) (80 mg/m2)
Trial: 28407009
Drug: Refractive error
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refractive error treatment coverage in Indigenous Australians
Trial: 28407009
Drug: Refractive error
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refractive error treatment coverage in non-Indigenous Australians
Trial: 28407009
Drug: Protective factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective factor for treatment of refractive error in Indigenous Australians
Trial: 21852546
Drug: H10407 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H10407 at doses of 10(7) CFU with bicarbonate
Trial: 19651565
Drug: Erythropoietin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (300 U/kg or 500 U/kg) administered every other day for 2 weeks
Trial: 12413642
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and Atenolol (beta-adrenergic antagonists)
Trial: 9366462
Drug: Intramuscular rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular rocuronium (1,000 microg/kg for infants and 1,800 microg/kg for children)
Trial: 9366462
Drug: Intravenous rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rocuronium (not specified in detail)
Trial: 3523298
Drug: Pirenzepine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (10 mg e.v./8 hours, starting the day before surgery to 10th day after it)
Trial: 3523298
Drug: Void period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Void period (without specific therapy)
Trial: 29969209
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist pretreatment for three days
Trial: 29969209
Drug: Conventional antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conventional antagonist protocols
Trial: 20056900
Drug: AMG 317
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 317 75 mg
Trial: 20056900
Drug: AMG 317
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 317 150 mg
Trial: 20056900
Drug: AMG 317
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 317 300 mg
Trial: 19343871
Drug: OXY‐TDS administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXY‐TDS administration
Trial: 15721109
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (sirolimus and paclitaxel)
Trial: 1888632
Drug: Flosequinan (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosequinan (oral, administered for 14 days)
Trial: 30361793
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel application with mock PBM‐LLLT
Trial: 30282144
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine 3 ml (Group A)
Trial: 30282144
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine 2 ml + physiological saline 1 ml (Group B)
Trial: 30282144
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine 1 ml + physiological saline 2 ml (Group C)
Trial: 30282144
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline 3 ml (Group D)
Trial: 20218984
Drug: Certoparin (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certoparin (3000 U of anti-factor Xa once daily)
Trial: 20218984
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UFH) (5000 IU t.i.d.)
Trial: 17485070
Drug: GaA1As laser,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaA1As laser, lambda=660nm, power of 30mW, energy dose of 2J/cm(2), applied directly and perpendicularly into the cavity in a single visit.
Trial: 17485070
Drug: No laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No laser therapy (control group).
Trial: 7695337
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg clavulanic acid with 2,000 mg amoxicillin
Trial: 7695337
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg clavulanic acid with 2,000 mg amoxicillin
Trial: 7017081
Drug: VM-26 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM-26 (60 mg/sq m on Day 1) plus CCNU (130 mg/sq m on Day 2), repeated every 6 weeks
Trial: 29169500
Drug: Heparin-bonded endoluminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded endoluminal grafts